Quality of life associated with visual loss: A time tradeoff utility analysis comparison with medical health states

Ophthalmology

Volumn 110, Issue 6, 2003, Pages 1076-1081

  Brown, Melissa M ^a,b   Brown, Gary C ^a,b   Sharma, Sanjay ^a,c   Busbee, Brandon ^a,b  

^a CENTER FOR VALUE BASED MEDICINE   (United States)

^b WILLS EYE HOSPITAL   (United States)

^c Queen's Medical College   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HEALTH STATUS; HUMAN; INTERVIEW; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL LITERATURE; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; STANDARDIZATION; VISUAL ACUITY; VISUAL IMPAIRMENT;

EID: 0037645977     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-6420(03)00254-9     Document Type: Article

References (53)

1. Sackett DL, Straus SE, Richardson WS, et al. Evidence-Based Medicine. How to Practice and Teach EBM, 2nd ed. New York: Churchill Livingstone, 2000;1-12.
2. Multicenter trial for retinopathy of prematurity. Snellen visual acuity and structural outcome at 51/2 years after randomization. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Arch Ophthalmol 1996;114:417-24.
3. Ferris FL 3rd, Kassoff A, Bresnick GH, Bailey I. New visual acuity charts for clinical research. Am J Ophthalmol 1982;94:91-6.
4. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 1. Early Treatment Diabetic Retinopathy Study Research Group. Arch Ophthalmol 1985;103:1796-806.
5. Brown MM, Brown GC. Outcome of corneal transplantation [editorial]. Br J Ophthalmol 2002;86:2-3.
6. Brown MM, Brown GC, Sharma S. Value-based medicine [editorial]. Evidence-Based Eye Care 2002;3:8-9.
7. Brown MM, Brown GC, Sharma S, et al. Utility values associated with blindness in an adult population. Br J Ophthalmol 2001;85:327-31.
8. Brown GC, Brown MM, Sharma S. Health care in the 21st century. Evidence-based medicine, patient preference-based quality and cost-effectiveness. Qual Manag Health Care 2000; 19:23-31.
9. Brown GC, Brown MM, Sharma S, et al. Cost-effectiveness of therapy for threshold retinopathy of prematurity. Pediatrics 1999;104:e47.
10. Brown GC, Brown MM, Sharma S. Incremental cost effectiveness of laser photocoagulation for subfoveal choroidal neovascularization. Ophthalmology 2000;107:1374-80.
11. Sharma S, Brown GC, Brown MM, et al. The cost-effectiveness of grid laser photocoagulation for the treatment of diabetic macular edema: results of a patient-based cost-utility analysis. Curr Opin Ophthalmol 2000;11:175-9.
12. Sharma S, Brown GC, Brown MM, et al. The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 2001;108:2051-9.
13. Redelmeier DA, Detsky AS. A clinician's guide to utility measurement. In: Bergus GR, Cantor SB, eds. Primary Care. Clinics in Office Practice. Philadelphia: WB Saunders, 1995; 271-80.
14. Brown MM, Brown GC, Sharma S, Shah G. Utility values and diabetic retinopathy. Am J Ophthalmol 1999;128:324-30.
15. Brown GC. Vision and quality of life. Trans Am Ophthalmol Soc 1999;97:473-511.
16. Brown GC, Sharma S, Brown MM, Kistler J. Utility values and age-related macular degeneration. Arch Ophthalmol 2000; 118:47-51.
17. Brown MM, Brown GC, Sharma S, Hollands H. Quality of life and systemic comorbidities in patients with ophthalmic disease. Br J Ophthalmol 2002;86:8-11.
18. Brown MM, Brown GC, Sharma S, et al. Quality of life with visual acuity loss from diabetic retinopathy and age-related macular degeneration. Arch Ophthalmol 2002;120:481-4.
19. Schrader GD. Subjective and objective assessments of medical comorbidity in chronic depression. Psychother Psychosom 1997;666:258-60.
20. Rothwell PM, McDowell Z, Wong CK, Dorman PJ. Doctors and patients don't agree: cross sectional study of patients' and doctors' perceptions and assessments of disability in multiple sclerosis. BMJ 1997;314:1580-3.
21. Lunde IM. Patients' perceptions: a shift in medical perspective. Scand J Prim Health Care 1993;11:98-104.
22. Brown GC, Brown MM, Sharma S. Difference between ophthalmologists' and patients' perceptions of quality of life associated with age-related macular degeneration. Can J Ophthalmol 2000;35:127-33.
23. Kassirer JP. Adding insult to injury. Usurping patients' prerogatives. N Engl J Med 1983;308:898-901.
24. Angell M. Patients' preferences in randomized clinical trials [editorial]. N Engl J Med 1984;310:1385-7.
25. Kassirer JP. Incorporating patients' preferences into medical decisions. N Engl J Med 1994;330:1895-1896.
26. Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. Med Care 2000;38:583-637.
27. National Library of Medicine. Available at: http://www. ncbi.nlm.nih.gov/PubMed. Accessed 2/2/03.
28. Krumins PE, Fihn SD, Kent DL. Symptom severity and patients' values in the decision to perform transurethral resection of the prostate. Med Decis Making 1988;8:1-8.
29. Jansen SJ, Stiggelbout AM, Wakker PP, et al. Patients' utilities for cancer treatments: a study of the chained procedure for the standard gamble and time tradeoff. Med Decis Making 1998;18:391-9.
30. Stiggelbout AM, Kiebert GM, Kievet J, et al. Utility assessment in cancer patients: adjustment of time tradeoff scores for the utility of life years and comparison with standard gamble scores. Med Decis Making 1994;14:82-90.
31. Brown GC, Brown MM, Sharma S, et al. Quality of life associated with diabetes mellitus in an adult population. J Diabetes Complications 2000;14:18-24.
32. Smith RD, Hall J, Gurney H, Harnett PR. A cost-utility approach to the use of 5-fluorouracil and levamisole as adjuvant therapy for Duke's C colonic carcinoma. Med J Aust 1993;158:319-22.
33. Tsevat J, Solzan JG, Kuntz RM, et al. Health values of patients infected with human immunodeficiency virus. Relationship to mental health and physical functioning. Med Care 1996;34:44-57.
34. Duncan PW, Lai SM, Keighley J. Defining post-stroke recovery: implications for design and interpretation of drug trials. Neuropharmacology 2000;39:835-41.
35. Gore JM, Granger CB, Simmons ML, et al. Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries. Circulation 1995;92:2811-8.
36. Ortega A, Dranitsaris G, Sturgeon J, et al. Cost-utility analysis of paclitaxel in combination with cisplatin for patients with advanced ovarian carcinoma. Gynecol Oncol 1997;66:454-63.
37. Bosch JL, Tetteroo E, Mali WP, Hunink MG. Iliac artery occlusive disease: cost-effectiveness analysis of stent placement versus percutaneous transluminal angioplasty. Dutch Iliac Stent Trial Study Group. Radiology 1998;208:641-8.
38. Laupacis A, Bourne R, Rorabeck C, et al. The effect of elective total hip replacement on health-related quality of life. J Bone Joint Surg Am 1993;75:1619-26.
39. Laupacis A, Keown P, Pus N, et al. A study of the quality of life and cost-utility of renal transplantation. Kidney Int 1996; 50:235-42.
40. Sackett DL, Torrance GW. The utility of different health states as perceived by the general public. J Chronic Dis 1978;31:697-704.
41. McLeod RS, Churchill DN, Lok AM, et al. Quality of life of patients with ulcerative colitis preoperatively and postoperatively. Gastroenterology 1991;101:1307-13.
42. Miyamoto JM, Eraker SA. Parameter estimates for a QALY utility model. Med Decis Making 1985;5:191-213.
43. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes, 2nd ed. New York: Oxford University Press, 1999; 52-204.
44. Brown GC, Brown MM, Sharma S. Cost-utility analysis [letter]. Arch Intern Med 2001;134:625-6.
45. Torrance GW. Utility approach to measuring health-related quality of life. J Chronic Dis 1987;40:593-603.
46. Boisjoly H, Gresset J, Fontaine N, et al. The VF-14 index of functional visual impairment in candidates for a corneal graft. Am J Ophthalmol 1999;128:38-44.
47. Broman AT, Munoz B, West SK, et al. Psychometric properties of the 25-item NEI-VFQ in a Hispanic population: Proyecto VER. Invest Ophthalmol Vis Sci 2001;42:606-13.
48. Digest of Educational Statistics. Available at: http://www. nces.ed.gov/pubs2000/digest99/d99t386.html. Accessed 9/17/2001.
49. Hollands H, Lam M, Pater J, et al. Reliability of the time trade-off technique of utility assessments in patients with retinal disease. Can J Ophthalmol 2001;36:202-9.
50. Brown GC, Brown MM, Sharma S, et al. The reproducibility of ophthalmic utility values. Trans Am Ophthalmol Soc 2001; 99:199-203; discussion 203-4.
51. World Health Organization Report 2000. Available at: http://www.who.int/health-systems-performance/whr2000.htm. Accessed: 9/21/2001.
52. Brown MM, Brown GC, Sharma S, et al. Physician manpower and health care expenditures in the United States: a thirty-year perspective. J Health Care Finance 2001;27:55-64.
53. Braae R, McNee W, Moore D. Managing pharmaceutical expenditure while increasing access. The pharmaceutical management agency (PHARMAC) experience. Pharmacoeconomics 1999;16:649-60.